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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is frequently
impervious to curative treatment efforts. Similar to other cancers associated with prolonged exposure to carcinogens,
HNSCCs often have a high burden of mutations, contributing to substantial inter- and intra-tumor heterogeneity. The
heterogeneity of this malignancy is further increased by the rising rate of human papillomavirus (HPV)-associated
(HPV+) HNSCC, which defines an etiological subtype significantly different from the more common tobacco and
alcohol associated HPV-negative (HPV-) HNSCC. Since 2011, application of large scale genome sequencing projects by
The Cancer Genome Atlas (TCGA) network and other groups have established extensive datasets to characterize
HPV- and HPV+ HNSCC, providing a foundation for advanced molecular diagnoses, identification of potential
biomarkers, and therapeutic insights. Some genomic lesions are now appreciated as widely dispersed. For example,
HPV- HNSCC characteristically inactivates the cell cycle suppressors TP53 (p53) and CDKN2A (p16), and often amplifies
CCND1 (cyclin D), which phosphorylates RB1 to promote cell cycle progression from G1 to S. By contrast, HPV+ HNSCC
expresses viral oncogenes E6 and E7, which inhibit TP53 and RB1, and activates the cell cycle regulator E2F1.
Frequent activating mutations in PIK3CA and inactivating mutations in NOTCH1 are seen in both subtypes of
HNSCC, emphasizing the importance of these pathways. Studies of large patient cohorts have also begun to
identify less common genetic alterations, predominantly found in HPV- tumors, which suggest new mechanisms relevant
to disease pathogenesis. Targets of these alterations including AJUBA and FAT1, both involved in the regulation
of NOTCH/CTNNB1 signaling. Genes involved in oxidative stress, particularly CUL3, KEAP1 and NFE2L2, strongly
associated with smoking, have also been identified, and are less well understood mechanistically. Application of
sophisticated data-mining approaches, integrating genomic information with profiles of tumor methylation and
gene expression, have helped to further yield insights, and in some cases suggest additional approaches to stratify
patients for clinical treatment. We here discuss some recent insights built on TCGA and other genomic foundations.
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Tumor heterogeneityBackground
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer, with annual incidence of
600,000 cases worldwide [1]. Anatomically, head and
neck cancer regions include the oral cavity, the pharynx
(nasopharynx—behind the nose; oropharynx—soft pal-
ate, base of the tongue and the tonsils; hypophar-
ynx—the lowest part of the pharynx), the larynx, the
paranasal sinuses, the nasal cavity and the salivary glands* Correspondence: Tim.Beck@Fccc.edu; Erica.Golemis@fccc.edu
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vided into two broad classes: human papillomavirus
(HPV)-associated (HPV+) and HPV-negative (HPV-)
disease. The majority of HPV-negative HNSCC arises
from the larynx and oral cavity [3, 4], although a small
fraction of cases originates in the oro- and hypopharynx.
HPV+ disease is typically found in the oropharynx, with
a minority of cases detected in the larynx and oral cavity
[5]. As of 2016, the majority of HNSCC is HPV- disease,
and is most commonly associated with tobacco use and
heavy alcohol consumption [6]. The exception is oropha-
ryngeal HNSCC, 60-70 % of which is HPV+ in North
America and Europe (significant geographic variationarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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[3, 5, 7]). Over 150 types of HPV have been identified,
with HPV subtype 16 (HPV–16) identified as the most
oncogenic, detected in over 90 % of HPV+ oropharyn-
geal cancers [8]. HPV+ HNSCC is typically diagnosed in
a younger patient population (6th decade of life; [5, 9])
and its prevalence has dramatically increased since the
1980’s (then only detected in 16 % of oropharyngeal can-
cer; [7, 9]). HPV- HNSCC is generally diagnosed in an
older patient population (7th decade of life), often pre-
sents with locally advanced or metastatic features, and
has a relatively poor prognosis compared to HPV+ tu-
mors [5, 10].
Both HPV+ and HPV- HNSCC are treated with a
combination of surgery, radiation and adjuvant chemo-
therapy. Treatment specifics vary depending on ana-
tomic site and disease stage. In general, low stage
tumors are treated with surgery, followed by radiation if
positive surgery margins are detected. For more ad-
vanced cases treatment includes surgery, if possible,
followed by radiation with or without adjuvant chemo-
therapy [1, 9, 11]. In spite of significant improvements,
including the introduction of targeted and immunother-
apies (most prominently, immune checkpoint inhibitors
targeting cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4) and programmed cell death protein 1 (PD-1)
[12]), as of 2015 the relative 5-year survival rate is only
approximately 25–40 % for HPV- and 70–80 % for HPV
+ HNSCC [1, 13, 14]. To fully capture the diversity of
HNSCC and to gain clinically meaningful insights that
can improve treatment, it seems critical to define the full
spectrum of molecular alterations and the heterogeneity
associated with this pathology.
At no prior point in time has it been possible to de-
scribe the molecular landscape of the various, mostly
anatomically defined cancers with as much detail and
precision as is possible today [15–17], based on con-
certed efforts to uncover the genomic (most advanced),
epigenomic, proteomic and transcriptomic changes that
occur as healthy tissue turns malignant, metastatic and
resistant to treatment [18]. The Cancer Genome Atlas
(TCGA) network and others have periodically published
datasets on many cancers [15, 17], including extensive
analyses of HPV- and to a lesser degree HPV+ HNSCC
(Table 1; [17, 19–24]). Amongst non-lung and non-skin
tumor types, head and neck cancer has one of the high-
est rates of non-synonymous mutations and a high de-
gree of genomic instability [15, 16, 25, 26], which
contribute to the enormous heterogeneity of HNSCC
[19, 24]. Since large-scale datasets began to appear in
2011 [20, 22], a number of groups have performed inte-
grated bioinformatics, translational, and clinical analyses
that leverage the genomic resources, suggesting new re-
search directions. This review summarizes and highlightspotential therapeutic opportunities in HPV- and HPV+
HNSCC based on the analysis of high throughput data
published by the TCGA network and others.
Foundational genomic datasets
The pathophysiological differences between HPV+ and
HPV- HNSCC necessitate that genomic analyses apply
rigorous classification methods for HPV dependence in
clinical samples [10, 22, 27]. HPV status is most com-
monly determined by polymerase chain reaction (PCR)
or in situ hybridization (ISH) to detect HPV genetic ma-
terial, or by immunohistochemical (IHC) staining for the
tumor suppressor p16 (CDKN2A), which is induced as a
consequence of HPV-associated transformation [28]. p16
IHC staining is greatly increased as a result of HPV in-
fection, and is a reliable proxy for positive HPV status in
primary tumors of the oropharynx [28]. Virally encoded
proteins target the cell cycle regulator retinoblastoma 1
gene (RB1), providing one potential feedback mecha-
nisms for enhancing expression of p16 ([29], and dis-
cussed further below). Alternatively, it has been shown
that upregulation of p16 can also occur as a cellular re-
sponse to the infection itself, through induction of the
histone 3 lysine-27 (H3K27) specific demethylases
KDM6A and KDM6B [30–32]. For other anatomic sites,
the true positive rate for p16 IHC staining falls below
50 %, reflecting the rarity of HPV-associated tumors out-
side of the oropharynx [28, 33]. High p16 expression
also occurs in about 5 % of HPV- cases, for reasons that
are at present unclear [28]. For these reasons, the TCGA
network took extensive measures to ensure proper HPV
classification of each tumor: in addition to p16 staining
and ISH, whole HPV genome sequencing as well as HPV
RNA-Seq was performed. HPV positive cases were clas-
sified as such if > 1000 RNA-Seq reads aligned to viral
genes E6 and E7 [19].
The TCGA network analyzed 243 HPV-negative and
36 HPV-positive tumors using multiple platforms (RNA
sequencing, DNA sequencing, reverse phase protein
array (RPPA), DNA methylation profiling and miRNA
sequencing) to define the molecular landscape of this
malignancy [19, 34]. Most of the patients in the TCGA
cohort were male (~70 %) and heavy smokers (51 mean
pack years; [19]), closely resembling the general HPV-
HNSCC patient population [1, 11]. Tumors predomin-
antly originated from the oral cavity (n = 172; 62 %; 160/
172 HPV- and 12/172 HPV+) and the larynx (n = 72;
26 %; 71/72 HPV- and 1/72 HPV+), with only a few
cases originating from the oropharynx (n = 33; 12 %; 11/
33 HPV- and 22/33 HPV+) and only two from the hypo-
pharynx (1/2 HPV+ and 1/2 HPV-).
Beyond the work of the TCGA network, additional
genomic sequencing studies (Table 1) were performed
by Stransky et al. (53 HPV- and 11 HPV+; [22]), Agrawal
Table 1 High-throughput genomic studies of HNSCC. The most frequently altered genes described in seven studies are shown,















HPV- HPV- N/A (NPC) N/A (Tongue) N/A (OSCC) HPV- N/A
n = 243 n = 69 n = 128 n = 34 (YT 16, OT 28) n = 35-40 n = 63 n = 28
TP53 (84 %, M) TP53 (81 %, M) TP53 (17 %, M/D) TP53 (94 %, 57 %, M) CDKN2A
(74 %, D)
TP53 (73 %, M) TP53 (79 %, M)
CDKN2A
(57 %, M/D)
CDKN2A (33, M/D) CDKN2A/B
(13 %, M/D)
CSMD1
(25 %, 75 %, D)
TP53 (66 %, M) CDKN2A
(25 %, M/Dc)
NOTCH1 (14 %, M)
let-7c (40 %, miRNA) MDM2 (16 %, A) ARID1A
(11 %, M/D)
PIK3CA (0 %, 11 %, M);
(30 %, 70 %, A)
FAT1 (46 %, M/D) SYNE1 (22 %, M) RELN (14 %, M)
PIK3CA (34 %, M/A) MLL2 (16 %, M) SYNE1 (8 %, M) CDKN2A (6 %, 4 %, M);
(55 %, 65 %, D)
TP63 (26 %, A) CCND1 (22 %, Ac) SYNE1 (14 %, M)
FADD (32 %, A) NOTCH 1
(16 %, M)
ATG13 (6 %, M/D) FADD/CCND1
(40 %, 65 %, A)
CCND1 (23 %, A) MUC16 (19 %, M) EPHA7 (11 %, M)
FAT1 (32 %, M/D) CCND1 (13 %, A) MLL2 (6 %, M) FAT1 (6 %, 25 %, M);
(50 %, 35 %, D)
MAML1 (23 %, D) USH2A (18 %, M) FLG (11 %, M)
CCND1 (31 %, A) PIK3CA (13 %, M) PIK3CA (6 %, M/A) EGFR (20 %, 50 %, A) EGFR (17 %, A) FAT1 (14 %, M) HRAS (11 %, M)
NOTCH1/2/3
(29 %, M/D)
PIK3CB (13 %, M/A) CCND1 (4 %, A) NOTCH1
(25 %, 18 %, M)
TNK2 (17 %, A) LRP1B (14 %, M) PIK3AP1 (11 %, M)
TP63 (19 %, A) UBR5 (13 %, M/D) NOTCH3
(4 %, M)
HLA-A (0 %, 14 %, M) AKT1 (14 %, A) ZFHX4 (14 %, M) RIMBP2 (11 %, M)
EGFR (15 %, M/A) EGFR (12 %, A) FGFR2 (4 %, M) CASP8 (6 %, 11 %, M) SRC (14 %, A) NOTCH1 (13 %, M) SI (11 %, M)
HPV+ HPV+ HPV+ HPV+
n = 36 n = 51 n = 11 n = 4
E6/7 (100 %) E6/7 (100 %) E6/E7 (100 %) E6/E7 (100 %)
PIK3CA (56 %, M/A) PIK3CA (22 %, M) PIK3CA (27 %, M) EPHB3 (25 %, M)
TP63 (28 %, A) TP63 (16 %, M/A) RUFY1 (18 %, M) UNC5D (25 %, M)
TRAF3 (22 %, M/D) PIK3CB (13 %, M/A) EZH2 (18 %, M) NLRP12 (25 %, M)
E2F1 (19 %, A) FGFR3 (14 %, M) CDH10 (18 %, M) PIK3CA (25 %, M)
let-7c (17 %, miRNA) NF1/2 (12 %, M) THSD7A (18 %, M) TM7SF3 (25 %, M)
NOTCH1/3 (17 %, M) SOX2 (12 %, A) FAT4 (18 %, M) ENPP1 (25 %, M)
FGFR3 (11 %, F/M) ATM (10 %, D) KMT2D (18 %, M) NRXN3 (25 %, M)
HLA-A/B (11 %, M/D) FLG (12 %, M) ZNF676 (18 %, M) MICAL2 (25 %, M)
EGFR (6 %, M) MLL3 (10 %, M) MUC16 (18 %, M)
N/A HPV status not available, NPC nasopharyngeal cancer, YT young tongue, OT old tongue, OSCC oral squamous cell carcinoma, M mutation, A amplification, D
deletion, F fusion
aData was accessed using cBioportal [38, 39]
bvalues for A and D are approximations
cpercentages are not based on the 63 cases, because CNAs were not analyzed for all cases
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oral squamous cell carcinoma; likely HPV-negative;
[35]), Seiwert et al. (69 HPV- and 51 HPV+; [21]), and
Pickering et al. (34 squamous cell carcinoma of the oral
tongue; likely HPV-negative; [36]). These predominantly
relied on a single platform (exome/massively parallel se-
quencing) for data acquisition. In addition, Lin et al.
have sequenced 128 cases of nasopharyngeal carcinomas
(NPC; likely HPV-; [37]).The TCGA dataset [19] is conveniently accessible
through cBioportal [38, 39], as are the datasets from
Stransky et al., Agrawal et al. [20, 22], and the NPC
study [37]. The 279 patient TCGA dataset provides the
most extensive tumor profiles, including mutational data
from whole exome sequencing, identification of somatic
copy number alterations using the GISTIC algorithm
[40], mRNA expression data (RNA-Seq V2 RSEM), and
protein expression data for a total of 165 combined
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array/microarray; [38, 39, 41]). The other three datasets
accessible through cBioPortal predominantly cover som-
atic mutations. The dataset for Pickering et al. [35] is
available through Gene Expression Omnibus (GEO;
[42]); the remaining studies provide access to datasets
via links provided in the original publications. Table 1
summarizes the top alterations detected in each study
for HPV- and, if available, HPV+ cases. Certain alter-
ations were detected across several studies; whereas, a
significant number of alterations were not uniformly
detected, potentially due to the variation in detection
platforms, disease heterogeneity and significant demo-
graphic differences.
Common genomic defects: HPV+ and HPV-
Copy number alterations (CNA) are frequent in HNSCC
[26] and are highly concordant across most of the gen-
ome for HPV- and HPV+ cases [19, 43]. One of the
most frequently amplified regions (in approximately 15–
30 % of cases [19]) is on chromosome 3q and includes
the anti-apoptotic kinase protein kinase C (PIK3CA),Fig. 1 The genomic profile of HNSCC. a Percent alteration for each listed g
in b cell cycle, c RTK/RAS/PI(3)K signaling, and d differentiation associated
Network dataset [19]. Diff. = differentiation; RTK = receptor tyrosine kinaseand the transcription factors TP63 and SOX2 [44].
Additional amplifications found in both the HPV+ and
HPV- disease subtypes include chromosomes 5p and 8q
[19, 43], which encompass telomerase TERT (5p) and
the oncogene MYC (8q). Commonly seen deletions
prominently cover parts of chromosome 3p and 8p,
impacting two tumor suppressor genes: FHIT (3p; ex-
pression loss is associated with worse survival in
HNSCC [45]) and CSMD1 (8p; [19, 46, 47]). Losses in
3p and 8p and gains in 3q, 5p and 8q are also frequently
seen in squamous cell carcinomas (SQCC) of the lung
[48], highlighting important genomic similarities be-
tween SQCC and HNSCC [19, 43, 48].
The microRNA let-7c, a cell cycle regulator, is fre-
quently inactivated in both HPV- and HPV+ HNSCC in
the TCGA cohort (Fig. 1a and b). Depressed expression
of let7-c is associated with increased expression of
CDK4, CDK6, E2F1 and PLK1, kinases and translational
regulators important for progression through the cell
cycle [19, 49]. In depth analysis of TCGA microRNA
data has been used to test the hypothesis that expression
of 28 microRNAs selected based on in vitro experimentsene in HPV+ and HPV- tumors (x = 0 % of cases); dominant alterations
genes. Percentages are based on the The Cancer Genome Atlas
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 5 of 17could predict response to radiotherapy [50]. Patients
from the TCGA cohort with complete clinical annota-
tions were divided into three groups: radiation with
complete response (radiosensitive), radiation with tumor
progression (radioresistant), and not irradiated. This
analysis suggested that upregulation of miR-016, miR-29,
miR-150, miR-1254 and downregulation of let-7e corre-
lated with complete response to radiotherapy. Effects
were linked to ATM expression. Higher levels of ATM
correlated with increased radio-resistance, based on
RPPA data also provided by the TCGA [50]. These inter-
esting findings necessitate validation using additional
cohorts, but clearly indicate the potential value of ana-
lyzing microRNA expression in HNSCC.
One of the most commonly activated (mutationally or
due to amplification of the 3q chromosomal region)
genes in both HPV+ and HPV- cases in the TCGA
cohorts (56 and 34 %, respectively) and other studies
(Table 1; [21–23]) is PIK3CA, encoding the p110α cata-
lytic subunit of phosphinositol-3-kinase (Fig. 1; [19]). In
this regard, HNSCC is similar to many other cancers in
which PIK3CA is amongst the most commonly mutated
genes [18]. PIK3CA encodes a lipid kinase that regulates
signal propagation from multiple input sources [51],
including many of the receptor tyrosine kinases (RTKs)
relevant to HNSCC (Fig. 1c; [19, 52, 53]). Functionally,
PIK3CA regulates phosphorylation of AKT1, and mu-
tated PIK3CA has been shown to attenuate apoptotic
signals and support tumor invasion [54]. Additionally,
mutationally activated PIK3CA has been shown to sup-
port cyclin D activity [55]; thus, further emphasizing the
tremendous relevance of cell cycle dysregulation in head
and neck cancers [43, 56].
Lui et al. performed a focused whole-exome analysis of
151 HNSCC tumors (datasets from Stransky et al. and
Agrawal et al., plus 45 additional cases [20, 22]), specific-
ally exploring PI3K pathway mutations for therapeutic
opportunities [23], This analysis (which did not assess
CNAs) indicated the PI3K pathway was the most fre-
quently mutated oncogenic pathway (30.5 % of tumors,
46/151 [23]). PIK3CA in particular was mutated in
12.6 % of cases (19/151; [23]), which is substantially less
than the number of cases with mutated PIK3CA (21 %,
58/279) reported by the TCGA [19]. Nevertheless, as-
sessment of patient derived xenografts expressing wild
type PI3KCA or mutant PI3KCA and treated with ve-
hicle or the mTOR/PI3K inhibitor BEZ-235 [57] indi-
cated tumors with mutated PI3KCA were exquisitely
sensitive to the small molecule inhibitor, whereas tumors
without the mutation did not respond to the treatment
[23]. Several studies using pre-clinical models also demon-
strated that HNSCC with wild type PI3KCA is sensitive to
PI3K/mTOR inhibitors, particularly in combination with a
MEK inhibitor or in combination with radiation in thecontext of wild type p53 [58, 59]. Development of a large
number of PI(3)K inhibitors is ongoing, with several
promising compounds currently being tested in clinical
trials [60].
Another commonly altered gene in HNSCC is NOTCH1.
NOTCH1 is a transmembrane kinase frequently mutation-
ally inactivated (most commonly via missense or truncating
mutation) in both HPV+ and HPV- cases (13–26 % and 8–
17 %, respectively [19, 21]; Table 1). The role of the
NOTCH pathway is complicated and depends on the over-
all organization of the broader signaling network and on
the specific tissue type [61]. Exome sequencing of HNSCC
strongly implicated NOTCH1 as a tumor suppressor in this
malignancy, as close to 40 % (11/28) of NOTCH1 muta-
tions were truncating mutations predicted to be inactivating
[20]. This conclusion was supported by the observation that
NOTCH1 knockout mice developed tumors due to in-
creased oncogenic CTNNB1 signaling [62]. Additional
work in tongue carcinoma cells observed robust down-
regulation of CTNNB1 in the background of stable expres-
sion of NOTCH1 [63]. Another important feature of
NOTCH1 is its participation in reciprocal negative regula-
tion with p63 [64], a member of the p53 family found to be
activated with high frequency in HNSCC (19 and 28 % in
HPV- and HPV+ cases respectively, mostly due to amplifi-
cation [19]). In keratinocytes, overexpression of p63 in-
duced cell growth in part by suppression of p21 and thus
directly counteracting the growth suppressive input from
NOTCH1 [65]. The TCGA data supports this NOTCH1-
p63 paradigm in HNSCC, given the high incident of
NOTCH1 inactivating mutations and the significant inci-
dent of p63 activation. Of note, p63 is transcriptionally acti-
vated by two distinct promoters [66]; one of the two
resulting p63 variants contains an N-terminal transactiva-
tion domain (TAp63), whereas, the other transcript lacks
the N-terminal domain and is termed ΔNp63 [66]. The two
p63 isoforms are functionally distinct [67], with ΔNp63
acting as a dominant negative regulator of p53 and with
TAp63 opposing cell cycle arrest and apoptosis [66, 68].
ΔNp63 is highly expressed in HNSCC [69] and indeed
inhibits NOTCH1 activity [65, 70].HPV-Negative HNSCC
Well prior to the advent of high throughput sequencing,
alterations in several genes, including inactivation or de-
letion of the tumor suppressors CDKN2A (p16; [71])
and TP53 (p53; [72]), and overexpression (via amplifica-
tion and elevated transcription) of the epidermal growth
factor receptor EGFR [73] had been identified as rele-
vant to the pathogenesis of HPV-negative HNSCC.
Based on TCGA analysis of genomic-scale data, the two
most commonly inactivated genes in HPV- tumors were
confirmed as TP53 (84 % of cases [19]; a percentage
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HPV- tumors; [21]) and Stransky et al. (73 % of 63 HPV-
tumors; [22])) and CDKN2A (4–74 % of cases Fig. 1a
and b and Table 1; [19, 21, 22]; the broad range is in part
due to the lack of CNA data for several of the studies
and the difficulties associated with sequencing of GC-
rich regions, which are found in CDKN2A [74, 75]).
Due to the high frequency of mutations in TP53
(Table 1), significant effort has been focused on elucidat-
ing the prognostic potential of this gene. Some work
suggests improved overall survival for patients with wild
type TP53 compared to patients with TP53 mutations
predicted to be functionally disruptive (i.e., nonsense
mutations or missense mutations disruptive to the L2 or
L3 DNA-binding domains [76]). Other reports indicated
that TP53 status is of low prognostic value when consid-
ered independently from other variables [77]. A multi-
tiered genomic analysis of 250 HPV-negative tumors in
2014 (TCGA dataset; approximately corresponding to
the cohort described above) confirmed that disruptive
TP53 mutations correlated with reduced survival; how-
ever, in this analysis, cases with TP53 mutations pre-
dicted to be non-disruptive also had significantly worse
survival outcomes compared to cases with wild type
TP53 [78]. Strikingly, this study identified TP53 muta-
tions as frequently co-occurring with deletions of
chromosomal region 3p (179 out of 250 cases), with the
combination associated with significantly worse survival
than was predicted for TP53 mutations or 3p deletions
considered independently [78]. Further stratification of
the 179 TP53-3p cases showed that elevated expression
of miR-548k (a microRNA encoded by a gene proximal
to cyclin D1 (CCND1) and the death receptor FADD at
11q13 and described as oncogenic in esophageal squa-
mous cell cancer [79]) predicted further reduction in
survival [78].
Efforts to elucidate the prognostic value of different
TP53 mutations have also led to the development of a
novel computation approach termed the Evolutionary
Action score of TP53-coding variants (EAp53; [80–82]).
EAp53 stratifies HNSCC patients with tumors harboring
TP53 missense mutations based on an estimated degree
of risk assigned to each mutation. The foundational
principles of this approach are based on previously iden-
tified TP53 “gain of function” mutations that enhanced
cell transformation and chemotherapy resistance [83].
EAp53 assigns functional sensitivity to sequence varia-
tions based on evolutionary substitutions for every
sequence position and calculates if substitutions correl-
ate with larger or smaller phylogenetic divergences to
determine “risk” [80, 82, 84]. HNSCC patients with p53
mutations classified using EAp53 as high-risk had
significantly worse survival outcomes and reduced
periods until distant metastases developed [80], as wellas increased resistance to chemotherapy [81]. As larger
datasets with clinical annotations become available, it
will be critical to refine and validate these models, and
to determine if and how TP53 status is suitable to pre-
dict efficacy of different therapeutic interventions.
CDKN2A regulates cell cycle progression by blocking
the activity of CCND1 (cyclin D1) and its associated ki-
nases, CDK6 and CDK4, which phosphorylate and in-
activate the tumor suppressor RB1 (Fig. 1b; [56, 85, 86]).
Inactivation of the CDKN2A gene was found in 57 % of
HPV- cases in the TCGA cohort [19]; however, other
studies produced discordant values for genomic alterations
of CDKN2A (ranging from 4 to 74 %; [20–22, 35, 36];
Table 1). Evaluation of CDKN2A status is somewhat com-
plicated by the fact that the gene is GC-rich (> 60 % of
bases are cytosine or guanine; [87]). Sequencing GC-rich
regions can be problematic because of their higher melting
temperature compared to GC-low regions, which is due to
base stacking and more stable secondary structure [74, 75].
Methylation-associated inactivation of CDKN2A (further
discussed below) is another important factor potentially
complicating assessment of the function status of this gene
[88–91]. Direct comparison of cases in the TCGA cohort
with homozygous deletions or predicted inactivating muta-
tions in CDKN2A versus wild type CDKN2A did not indi-
cate a survival difference. However, as with TP53,
subsequent refined analysis of CDKN2A status emphasized
that the patient cohort with low mRNA expression of
CDKN2A (RNA-seq: z < 3-fold) did have reduced survival
(p = 0.037; [56]). This observation is in accordance with
other work that indicated improved survival for patients
with p16-positive non-oropharyngeal squamous cell carcin-
oma [92]. Further emphasizing the importance of this
signaling axis is the fact that CCND1 is the most fre-
quently amplified gene in the TCGA cohort of HPV-
HNSCC cases, detected in 31 % of cases (confirming
earlier studies [19, 21, 22, 56]). Beck et al. reported that
high RNA expression of CCND1 (z > 2-fold) not only
correlated with reduced survival in the TCGA dataset
[19, 56], but also co-occurred frequently with CDKN2A
deletions (co-occurrence ratio: 0.817). Cases harboring
both, amplified CCND1 and deleted CDK2N2A had
much worse prognosis than cases without these alter-
ations [56].
In the TCGA cohort, EGFR was amplified in 12 % of
HPV- cases [19], the same % of cases with EGFR ampli-
fication was reported by Seiwert et al. [21]. Seiwert et al.
did not report significant incidence of alteration in
HER2 (also known as ERBB2), ERBB3 and ERBB4 and
the TCGA also only detected alterations of those genes
in a small number of cases (4–6 %; [19]). Nevertheless,
alterations in ERBB2 or ERBB3 have been directly linked
to resistance to EGFR-targeted therapy and are thus of
therapeutic relevance [93]. Mining of TCGA data
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with expression of HER2, and both, pHER2 and HER2
expression correlated with protein expression of EGFR
[93], providing some patient data in support of in vivo
results in which dual kinase inhibition of EGFR and
HER2 enhances response to cetuximab [94]. In addition,
the RTKs FGFR1 and IGF1R were identified with acti-
vating mutations in 10 and 4 % of HPV- HNSCC,
respectively, while no mutations of these kinases were
identified in HPV+ HNSCC tumors (Fig. 1a and c).
FGFR1 and IGFR1 participate in a signaling network
that includes EGFR and other ERBB family members
(Fig. 1c), and both can contribute to resistance to EGFR-
targeted therapeutics, the only type of targeted therapy
approved for HNSCC [73, 95, 96]. Functioning down-
stream of these RTKs, the GTPase HRAS was almost
exclusively altered in HPV- HNSCC (5 %), propagates
pro-proliferation and pro-survival signaling via the
BRAF-MEK-ERK axis, and provides alternative input to
activate PI3K (Fig. 1c; [97–99]).
For two additional genes, AJUBA and FAT1, almost all
detected alterations were found in HPV- tumors (Fig. 1a
and d). Both genes are involved in differentiation and
are linked to the NOTCH/CTNNB1 signaling pathway
as negative regulators [19, 100, 101]. The scaffolding
protein AJUBA, inactivated in 7 % of HPV- cases (0 % of
HPV+ tumors), has also been implicated in interactions
with Aurora-A kinase (AURKA), a critical regulator of
mitosis [102]. AURKA is overexpressed in a significant
percentage (7 %) of HNSCC cases and correlated with
diminished survival in an analysis of provisional TCGA
data (significant overlap with the published TCGA data-
set; [19, 103]). FAT1 is a member of the cadherin-like
protein family and has been described as a suppressor of
cancer cell growth based on a role in binding to and an-
tagonizing CTNNB1 [100]. FAT1 had previously been
shown to be mutated in roughly 7 % of 60 head and
neck tumors [100], but was detected to be inactivated
(missense/truncating mutations and homozygous dele-
tions) in a much greater percentage of HPV- cases (32 %;
versus inactivated in only 3 % of HPV+ cases; Fig. 1a and
d) analyzed by the TCGA network [19]. The discrepancy
may be due to a number of reasons, including differences
in sample processing, determination of HPV status, demo-
graphic factors, different acquisition platforms, and differ-
ently constructed analytical pipelines.
The TCGA analysis also identified a set of less well
studied alterations associated with oxidative stress, spe-
cifically involving CUL3, KEAP1 and NFE2L2 [19].
KEAP1 and NFE2L2 were exclusively altered in HPV-
HNSCC (Fig. 1a). KEAP1 was inactivated in 5 % of
cases and NFE2L2 was activated in 14 % of cases. Func-
tionally, NFE2L2 is a transcription factor that regulates
antioxidant and stress-responsive genes [104]. KEAP1complexes with the E3 ligase CUL3 (inactivated in 6 %
of HPV- cases) to polyubiquitinate NFE2L2 [105]; thus,
disruption of canonical KEAP1-CUL3 function promotes
NFE2L2 activity [19]. Intriguingly, in lung cancer, a
NFE2L2-centric gene signature has been proposed as
a valuable prognostic biomarker [106]. This may be
relevant because significant molecular similarities be-
tween HNSCC and lung squamous cell cancers
(SQCC) exist [19, 43, 48, 107], including shared dys-
regulation of KEAP1 and NFE2L2. Secondary analysis of
the TCGA dataset indeed revealed that DNA level
alterations of any member of the KEAP1/CUL3/RBX1
complex correlated with significantly reduced survival
(median survival of ~35 months versus ~72 months; [108]).
Lastly, the TCGA network detected co-amplification
of chromosome regions 11q13 and 11q22. Found within
region 11q22, an amplicon previously described in lung,
esophageal and cervical cancer [109–111], are the coding
sequences for BIRC2 and YAP1. BIRC2 encodes c-IAP1
and is a member of the inhibitor-of-apoptosis family
[112]. Functionally, BIRC2 inhibits caspase activity, in-
cluding the activity of CASP8 [112], and it has been
shown that BIRC2 plays an important role in the ubiqui-
tination and degradation of TRAF3 (tumor necrotizing
factor receptor-associated factor 3), a negative regulator
of NF-kB activity [113]. BIRC2 is more commonly
altered in HPV- HNSCC (7 % of cases versus 3 % of
cases in HPV+ HNSCC) and, as would have been predi-
cated based on functionality, CASP8 was also frequently
detected as inactivated through mutations or homozy-
gous deletion (11 % of HPV- cases; Fig. 1a). YAP1 is a
proto-oncogenic transcription factor downstream of
BIRC2 and associated with the Hippo pathway [114].
Amongst cancers analyzed by the TCGA, HNSCC had
the fifth highest incident of amplified YAP1 (6.3 % of
cases). Interestingly, a recent study found that YAP1
amplification strongly correlated with resistance to
cetuximab in vitro [115], which may reflect YAP1 associ-
ated upregulation of the EGFR ligand amphiregulin; fur-
ther investigations are needed to fully uncover the
precise mechanism of this type of resistance [115, 116].
Amplification of region 11q13 includes the region en-
coding the Fas-associated death domain gene (FADD;
established as frequently overexpressed in HNSCC [117]
and found to be amplified in 32 % of HPV- cases ana-
lyzed by the TCGA [19]). Importantly, FADD has been
implicated in increased lymph node metastasis in
HNSCC [117].
HPV-Positive HNSCC
At the molecular level, HPV+ carcinomas significantly
differ from HPV- cases, highlighted in great detail by the
TCGA network and others [10, 19, 21, 27, 92]. A signifi-
cant limitation of the TCGA study is the fact that only
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compensated for by the work of other groups (Table 1;
[21, 23, 34, 118]). Further analysis of additional tumors
is clearly needed; however, some conclusions can be
made in spite of the limited numbers of cases.
HPV+ HNSCC is defined by infection of tumor cells
with HPV. HPV DNA can exist either integrated into
the human genome or in a nonintegrated form [34, 119].
Upon infection, the HPV genome (8 kb) is first amplified
as extrachromosomal circular elements (episomes), some
of which may subsequently integrate into one or more
location within the host genome [119]. It has been re-
ported that HPV integration sites are randomly distrib-
uted throughout the genome [120]. In one study,
analysis of 35 of the 36 HPV+ TCGA HNSCC cases
identified HPV integration in 25 cases and uncovered
distinct gene expression and methylation patterns for
HPV integrated versus non-integrated HNSCC, suggest-
ing different pathogenic mechanisms [34]. Another study
published similar results for essentially the same group
of patients (36 HPV+ HNSCC), and detected HPV DNA
integration in 24/36 cases [119]. The general observation
regarding HPV integration is not unique to HNSCC, as
HPV+ cervical cancers include HPV integrated and non-
integrated cases [121]. Compared to episomal HPV
DNA, transcripts derived from integrated viral DNA
have been shown to be more stable and more strongly
associated with increased proliferative capacity of af-
fected cells [122]. It is likely that HPV integration, particu-
larly if within or proximal to key cancer related genes, is
important but not essential for the oncogenicity of HPV:
the better understood oncogenic contribution of the virus
is the production of different oncoproteins [34].
HPV oncoproteins include E6 and E7 (Fig. 1b; [122]),
which perform complementary actions in eliminating
negative regulators of the cell cycle. E6 binds p53 and
targets this tumor suppressor for proteosomal degrad-
ation [123]. Tumor suppressor RB1 interacts with E7,
which targets RB1 for degradation through association
with the cullin 2-ubiquitin-ligase complex [124–126]. As
E6 and E7 function through cell cycle dysregulation by
eliminating RB1 and TP53, very few alterations in add-
itional cell cycle regulators occur in HPV+ disease: in-
activation of CDKN2A, or TP53, or overexpression of
CDK6 or CCND1, occur seldom in HPV+ HNSCC. One
exception is the transcription factor E2F1, which is nor-
mally inhibited by RB1 (Fig. 1b; [56]); it is the only cell
cycle regulator identifier by the TCGA study as being
predominantly altered in HPV+ cases (19 % activated via
amplification of chromosome 20q11, seen in only in 2 %
of HPV- HNSCC; Fig. 1a and b).
Also associated with HPV+ disease is the RTK FGFR3,
which is activated in 11 % of cases through either muta-
tion or a gene fusion event, and the aforementionedTNF receptor associated factor TRAF3, inactivated in
22 % of cases (versus 1 % in HPV- disease). The FGFR3
fusion partner is TACC3, a protein critical for nucleation
of microtubules at the centrosome [127], aberrantly
expressed in some cancers and potentially targetable
with small molecules [128]. A FGFR3-TACC3 fusion was
first described in glioblastoma [129] and subsequently
detected in nasopharyngeal carcinoma and other HNSCCs
[130, 131]. This fusion event was detected in two of the 36
HPV+ and zero of the HPV- HNSCC TCGA cases [19].
Constitutive kinase activity of the FGFR3-TACC3 onco-
gene induces loss of mitotic fidelity and leads to aneu-
ploidy [129, 131]. In cases where present, FGFR3-TACC3
appears to be tumor driving and patients are likely to dis-
proportionally benefit from FGFR3 targeting therapy
[131]. TRAF3 has mostly been studied in immunological
processes and one of its main functions is regulation of
NFkB activity [132]. In subsequent studies in HNSCC,
functional analysis of TRAF3 has suggested a tumor sup-
pressive role of the gene when overexpressed, and in-
creased cell proliferation in the context of depleted
TRAF3 [133].Tumor heterogeneity
HPV- and HPV+ HNSCC share one particularly challen-
ging feature: tumor heterogeneity [24]. This aspect of
tumor biology has garnered significant attention in re-
cent years because of the immense clinical implications
in terms of prognosis, drug resistance and precision
medicine [134–136]. Extensive analysis of TCGA data
indicates that it is of high relevance in HNSCC [24, 137].
One approach to study HNSCC heterogeneity is based on
whole-exome sequencing (WES), which can be used to
determine the fraction of total sequenced DNA that con-
tains a given mutant allele: termed mutant-allele fraction
(MAF). The width of MAF distribution, normalized to the
median MAF value, constitutes the quantitative value of
intra-tumor heterogeneity, and has been termed mutant-
allele tumor heterogeneity (MATH; [137, 138]). Earlier
work indicated that HPV- tumors had significantly higher
heterogeneity than HPV+ tumors (though substantial even
for HPV+ cases; [137]), which would be predicated based
on the frequency of and genomic instability associated
with TP53 mutations, increased age and continuous
tobacco use [24].
Provocatively, in a ten-variable multivariate analysis of
TCGA HNSCC data incorporating MATH scores, no
prognostic significance of HPV status, N classification or
TP53 mutational status was determined [138]. While the
lack of significance in the multivariate analysis does not
suggest irrelevance of the three parameters, it strongly
suggests that further work is needed to unravel these
variables and to determine how much each parameter
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context of appreciated heterogeneity. For example, dis-
ruptive TP53 mutations [78] are strongly associated with
higher intra-tumor heterogeneity as calculated by
MATH (i.e., high MATH scores), and both TP53 muta-
tional status and high MATH scores, based on univariate
analysis, indicated reduced survival [78, 137].
Additional innovative and detailed analysis by McGra-
nahan et al. utilized TCGA datasets for nine tumor types,
including HNSCC, to highlight important aspects of can-
cer evolution and clonality [24]. In order to determine if
specific alterations were clonal (present in most/all tumor
cells sequenced and therefore considered “early” muta-
tions) or subclonal (present in a small fraction of cells and
considered “late” mutations) McGranahan et al. used
exome sequencing data and single-nucleotide polymorph-
ism arrays to calculate the confidence interval of the can-
cer cell fraction (CCF; proportion of cancer cells
harboring a given mutation; [139–141]) for a given
mutation. A 95 % confidence interval of ≥ 1 was used to
define clonal (“early”) mutations, and mutations with a
confidence interval of less than 1 were defined as subclo-
nal (“late”) mutations [24, 140–142]. In HNSCC, the ma-
jority of driver mutations were clonal, and CDKN2A and
TP53 were identified as almost exclusively clonal. Based
on the proportion of mutations, three mutational signa-
tures (previously defined [25]) were identified for HNSCC:
1) a signature with C > T transitions at CpG sites associ-
ated with spontaneous deamination of methylated cyto-
sines that strongly correlated with patient age at diagnosis
and was most prevalently linked to “early” mutations; 2) a
signature indicative of up-regulation of APOBEC cytosine
deaminases [143], seen in both “early” and “late” muta-
tions, although with significant prominence in “late” mu-
tations; and 3) a signature associated with smoking
induced mutations, seen predominantly with “early” muta-
tions [24]. McGranahan et al. did not differentiate be-
tween HPV+ and HPV- cases, which future studies should
do, particularly given that previous analysis of TCGA data
detected evidence that HPV infection was strongly associ-
ated with APOBEC-mediated mutagenesis in HNSCC
[144]. Furthermore, the same study suggested that
APOEC-mediated mutagenesis significantly contributes to
helical domain E545K and E542K gain of function muta-
tions in PIK3CA, one of the most frequently altered genes
in HNSCC (32 out of 58 PIK3CA mutations in the TCGA
cohort are E545K/E542K mutations; [19, 21, 144, 145]).
As an emerging concept for this disease, consideration
of germline variants may be relevant to fully appreciate
tumor heterogeneity. Recent analysis of TCGA data sug-
gested that 15 % (44 out of 291 cases; incompletely con-
gruent with the published TCGA dataset [19]) of
HNSCC cases have rare germline truncations, including
truncations in several genes important in the FanconiAnemia Pathway, specifically FANCA and FANCM,
which are involved in DNA repair [146, 147]. FANCM
mutations significantly correlated with increased somatic
mutational frequency in the complete HNSCC cohort
(mean age was 60.9 +/− 12.4 years; based on personal
correspondence with authors), whereas, FANCA had a
similar correlation with the frequency of somatic muta-
tions, but specific in cases defined as younger age (mean
age was 46.3 +/− 7.0 years) of onset (no indication re-
garding HPV status; [146]). Recent studies using murine
models have implicated MYH9 as a gene that induces
oral squamous cell carcinoma in the context of germline
mutations or knockout [148, 149]. MYH9 encodes for
non-muscle myosin II-A (NM II-A), best known for its
roles as a cytoskeletal protein and during embryonic
development [150]. Intriguingly, MYH9 may also acts as
a tumor suppressor, by regulating stabilization and nu-
clear retention of p53 [149]. MYH9 and MYH10 were
mutated in 4 and 5 % of cases, respectively within the
TCGA cohort of 279 patients [148]. No correlation with
HPV status was detected. Success of future clinical
efforts, particularly for targeted therapeutics, will likely
heavily depend on consideration of heterogeneity and
cancer evolution, guided by studies of spatio-temporal
differences in genomic alterations, including presence or
absence of germline mutations [134, 151].
Therapeutic insights
The majority of patients with HNSCC are treated with
surgery and/or radiation and in some cases adjuvant
chemotherapy [1, 3, 11, 27]. Treatment approaches for
HPV- and HPV+ cases remain very similar [1]. However,
because of the better prognosis and the younger age of
onset associated with HPV+ disease, therapeutic de-
intensification, currently only available as part of clinical
trials, for the treatment of patients with HPV+ HNSCC
is being actively explored [27, 152]. Thus far, the only
targeted therapeutic approved to treat HNSCC is the
monoclonal antibody cetuximab, designed to target the
extracellular region of EGFR (Fig. 2; [153]). The clinical
impact of cetuximab has been significant in some pa-
tients [154], but relatively modest overall [2, 73, 155].
Several small molecules, for example lapatinib (targeting
EGFR and HER2; [156]), afatinib (targeting EGFR and
HER2; [157]) and others (reviewed in [153]), have shown
some promise in the treatment of HNSCC. Inter- and
intra-disease heterogeneity are likely determining factors
that have thus far held back greater success of available
therapeutics, and represents one of the key challenges to
overcome [19, 24, 151]. Consideration of a single gene,
based on a single biopsy, does not seem sufficient to
maximize therapeutic interventions [73]. For example,
consideration of EGFR expression and/or amplification
does not correspond with response to EGFR inhibitors
Fig. 2 Potential therapeutic intervention based on genomic alterations. Therapeutics targeting of a cell cycle and b RTK/RAS/PI(3)K signaling
associated elements. Percentages are based on the The Cancer Genome Atlas Network report [19]. RTK = receptor tyrosine kinase
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that targeting EGFR may not be efficacious in the con-
text of extensively altered parallel or downstream signal-
ing components, including cell cycle regulators, due to
overlapping functional contributions [73, 158].
Figure 2 summarizes potentially promising targets
other than EGFR, based on available genomics data. The
drugs shown in Fig. 2 are examples of drugs currently in
clinical development for the treatment of HNSCC; re-
cent reviews provide more complete lists of available
drugs for each target [3, 159–161]. The near universality
of cell cycle dysregulation in HNSCC strongly recom-
mends investigation of CDK inhibitors [19, 56]. HPV-
HNSCC with functional CDKN2A and high levels of
phosphorylated RB1 may present the ideal molecular
background for effective treatment with CDK4/6 inhibi-
tors (Fig. 2; [56]). Furthermore, therapeutic targeting of
aberrant cell cycle activity may partially circumvent the
challenge presented by heterogeneity, given that clonal
status analysis of the TCGA HNSCC cohort indicated
that genes associated with cyclin-dependent kinases have
0 % of mutations arise in subclonal populations [24],
which suggests that cell cycle alterations arise early dur-
ing tumor development and are present in most if not
all tumor cells. A large number of CDK inhibitors are
currently in development [162] and the possibility of
RB1 phosphorylation status as a response predictive bio-
marker is encouraging [56]. PI3K [NCT01816984], FGFR
[NCT02558387], BRAF [NCT01286753], MEK [NCT01
553851], AKT [NCT01349933] and mTOR [NCT01051791] are further targets of potential therapeutic rele-
vance (Fig. 2b; [102, 103, 163, 164]). Additional promising
pre-clinical work has explored Second Mitochondria-
derived Activator of Caspases (SMAC)-mimetics, antago-
nists of inhibitors of apoptosis, which seem particularly
effective against HNSCC models with FADD/BIRC2 alter-
ations [165, 166]; particularly meaningful considering the
aforementioned high incident of FADD/BIRC2 alterations
in HNSCC (Table 1).
The perhaps most exciting recent development in the
treatment of cancer is immunotherapy [167]. Immuno-
therapy, specifically checkpoint blockade, has been tre-
mendously successful in some cases of non-small cell
lung cancer [168, 169], malignant melanoma [170] and
other cancers [171, 172]. Checkpoint inhibitors seem to
be particularly effective against tumors with high rates
of mutation, which suggests that a subpopulation of pa-
tients with HNSCC would benefit form this type of
therapy. Furthermore, HNSCC appears to be an
immunosuppressive disease commonly associated with
lymphopenia [173, 174] and in a few cases (7 % of HPV-
and 11 % of HPV+ HNSCC in the TCGA cohort) pre-
senting with specific mutations in HLA alleles and the
antigen processing machinery to reduce tumor immuno-
detection [19]. A substantial number of clinical trials are
currently exploring the applicability of immunotherapy
for the treatment of HNSCC, with primary focus on
immune checkpoint blockade via CTLA-4 and PD1 [12].
In brief, CTLA-4 and PD1 are expressed by T-cells and
function as negative regulators of T-cell activity, a
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Tumor cells frequently engage CTLA-4 or PD1 to
modulate T-cell activity and escape immunodetection
[172, 175]. Immune checkpoint blockade inhibits inter-
action of tumor cells with CTLA-4 or PD1; thus, block-
ing inactivation of T-cells [175]. Regarding HNSCC,
several phase III studies are currently exploring the util-
ity of checkpoint inhibitors; specifically, the humanized
monoclonal PD-1 specific antibody pembrolizumab
[NCT02564263, NCT02358031, NCT02252042], re-
cently approved for the treatment of melanoma and lung
cancer (two cancer types with high mutational burden;
[25, 26, 176–178]) and tremelimumab (fully human anti-
body against CTLA-4) with or without durvalumab (Fc
optimized monoclonal antibody against the PD1 ligand
1; NCT02551159). Initial results are expected to be pub-
lished in the near future [12]. It will be important to
determine if distinct molecular lesions found in HNSCC,
as summarized above, are prognostic for response to
these new treatments. In the case of immunotherapy,
considerations beyond the tumor may also be particu-
larly important; for example, early laboratory studies
have shown that the composition of the intestinal micro-
biota significantly impacts the efficacy of CTLA-4/PD-1
inhibitors [179, 180].Methylation in HNSCC
Future endeavors are likely to include more extensive
elucidation of the role of DNA methylation in HNSCC,
in part to substantiate publications based on the TCGA
dataset. DNA methylation is important in the regulation
of gene expression, and aberrant methylation has been
described for essentially all cancer types and as a critical
aspect of cancer genomics [181, 182]. Previously pub-
lished work suggests that HPV+ HNSCC has signifi-
cantly differentiated CpG island methylation compared
to HPV- cases, reflecting the notion that HPV+ and
HPV- HNSCC are distinct diseases on the genomic,
transcriptomic and methylomic level [183–185]. Com-
parative analyses of available HPV+ TCGA cases re-
vealed specific hypermethylated regions downstream of
CDKN2A, which correlated with increased transcription
of CDKN2A variant p14 (ARF; [184]). CDKN2A is also
frequently methylated (23–67 % of cases; [91]) to silence
expression of this tumor suppressor [88, 90, 186]; al-
though, degree of methylation and expression changes
can vary significantly among individual tumors [187].
The mechanistic and clinical ramifications of this obser-
vation are not yet understood. Another study of HPV+
HNSCC reported that a promoter methylation signature
of 5 genes, three with high methylation (GATA4, GRIA4,
IRX4) and two with low methylation (ALDH1A2 and
OSR2), correlated strongly with improved survival [188].The signature was validated across multiple cohorts.
Methylation patters in HPV+ HNSCC are significantly
distinct for cases with integrated HPV DNA and epi-
somal DNA [34, 119], a potentially important factor not
always considered.
Interestingly, prominent differential methylation of
three members of the zinc finger gene family, ZNF14,
ZNF160 and ZNF420, has been identified as suitable to
detect HNSCC with 100 % specificity in primary tissue
and saliva samples; subsequently, the three ZNF methyla-
tion signature was validated using the 273 TCGA cohort
[185]. For most of the methylomics driven studies of
HNSCC [183, 185, 188, 189], few cases were analyzed
(particularly for HPV+ cases) and additional work is
needed to better understanding and interpret the various
methylation patterns. How methylomics data is going to
be integrated into clinical practice for HNSCC remains
to be seen, although prognostic and diagnostic potential
of such information is apparent in some cancer types
[181, 185, 190]. No DNA methylation markers for HNSCC
have been accepted for clinical use to date [185].
Conclusions
Detailed profiling of HNSCC by the TCGA network and
other research groups has greatly enhanced our under-
standing of this malignancy. First and foremost, the
composite results have highlighted the tremendous in-
ter- and intra-tumor heterogeneity, complicated by the
increasing incidence of HPV-associated tumors. Efforts
have started to focus on classifying tumors based on mo-
lecular profiles [191–193]; however, inroads in terms of
improved survival have not substantially materialized
yet. The next phase is likely to require multi-platform
analysis of many more HPV- and HPV+ tumors, ideally
sufficient to cover each anatomic site to enable action-
able conclusions. In parallel, laboratory research and
clinical trials have to continue to provide data that can
guide therapeutic strategies based on molecularly de-
fined parameters and higher-order interactions. Progress
continues to be made and the status quo for patients
with HNSCC is likely to continue to improve over the
next decade.
The greatest potential therapeutic advantage to come
from the detailed parsing of HNSCC heterogeneity is
advanced and eventually precise treatment with im-
munotherapy. For example, consistent identification of
tumors with highly immunogenic alterations would sig-
nificantly help guide therapeutic decision-making [194].
Immunotherapy has been remarkably successful against
many types of cancer, with particularly striking successes
against other carcinogen-associated cancers, such as
lung cancer [169, 195] and melanoma [170, 196]. High
mutation burden, common for many sub-types of
HNSCC [19, 24, 25], and carcinogen-associated genomic
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munotherapy [194, 197]. Leveraging and advancing
current knowledge to optimize selection of HNSCC
cases for treatment with immunotherapy should be a
top priority and could greatly enhance the many ongoing
clinical trials [12]. The perhaps most promising ap-
proach to eradicate HPV+ HNSCC is extended use of
the available vaccine, which currently appears to be suc-
cessful in reducing rates of cervical cancer [198, 199]
and would presumably be as successful in reducing the
rate of HPV+ HNSCC.
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receptor; located at 11q26.3; IHC: immunohistochemistry; antibody-based
tissue staining; IRX4: Iroquois homeobox 4; located at 5p15.3; ISH: in situ
hybridization; uses labeled complementary DNA or RNA to localize specific
DNA or RNA in tissue; KEAP1: kelch like ECH associated protein 1; interacts
with NFE2L2 in a redox-sensitive manner; located at 19p13.2; let-
7c: MIRLET7C also known as microRNA let-7c; short non-coding RNA
involved in post-translational regulation of genes; located at 21q21.1;
MAF: mutant-allele fraction; fractional of total sequenced DNA with a given
mutant allele based on whole-exome sequencing; MATH: mutant-allele
tumor heterogeneity; width of the mutant-allele fraction distribution
normalized to the median MAF value; MEK: mitogen-activated protein kinase
kinase; group of kinases also known as MAP2K; MAPKK or MKK; miRNA: micro
RNA; small non-coding RNA molecule; mRNA: messenger ribonucleic acid;
mTOR: mechanistic target of rapamycin; serine/threonine
phosphatidylinositol kinase-related kinase; located at 1p36.2; MYC: v-myc
avian myelocytomatosis viral oncogenes homolog; nuclear phosphoprotein
and transcription factor; located at 8q24.21; MYH9: Nonmuscle Myosin Heavy
Chain II-A (also known as NMHC-II-A); cytoskeleton protein; N
classification: part of the TNM classification of malignant tumours staging
notation system; describes cancer positive regional lymph nodes; ranges
from N0 (tumor cells absent from regional lymph nodes) to N3 (tumor cells
detected in distant lymph nodes); NFE2L2: transcription factor; regulates
expression of genes with antioxidant response elements; located at 2q31;
NFkB: NFKB1; nuclear factor of kappa light polypeptide gene enhancer in
B-cells 1; transcription regulator; located at 4q24; NOTCH: highly conserved
signaling pathway; may also refer to NOTCH1; a type 1 single pass
transmembrane receptor; located at 9q34.3; NPC: nasopharyngeal cancer;
originates in the upper part of the throat behind the nose and near the base
of the skull; OSCC: oral squamous cell carcinoma; OSR2: odd-skipped related
transcription factor 2; located at 8q22.2; p14(ARF): alternative reading frame
protein product of the CDKN2A locus; inhibits the E3 ubiquitin protein ligase
MDM2 (p53 degradation); PCR: polymerase chain reaction; PD-1: PDCD1;
programmed cell death 1; member of the immunoglobulin superfamily
expressed on pro-B and T cells; located at 2q37.3;
PI(3)K: phosphatidylinositol-4,5-bisphosphate 3-kinase; family of intracellular
enzymes; PI3KCA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha; codes for p110α; the catalytic subunit; located at 3q26.3;
PLK1: polo-like kinase 1; serine/threonine kinase; highly expressed during
mitosis; located at 16p12.2; RB1: retinoblastoma 1; negative regulator of the
cell cycle; located at 13q14.2; RNA-Seq: RNA sequencing; next-generation
sequencing to detect and quantify RNA; RPPA: reverse phase protein array;
high-throughput antibody-based protein detection technique; RTK: receptor
tyrosine kinases; large family of transmembrane tyrosine kinases; S: synthesis
phase; phase of the cell cycle during which DNA is replicated; follows G1
and precedes G2; SOX2: SRY-box 2; transcription factor; located at 3q26.3-
q27; SQCC: squamous cell carcinomas; TACC3: transforming, acidic coiled-coil
containing protein 3; motor spindle protein; located at 4p16.3; TCGA: the
Cancer Genome Atlas; TERT: telomerase reverse transcriptase;
ribonucleoprotein polymerase; maintains telomere ends; located at 5p15.33;
TP53: tumor protein p53; transcription factor and tumor suppressor; located
at 17p13.1; TP63: tumor protein p63; p53 family transcription factor; located
at 3q28; TP73: tumor protein p73; member of the p53 family of transcription
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 13 of 17factors; located at 1p36.3; TRAF3: TNF receptor associated factor 3; member
of the TNF receptor associated factor protein family; located at 14q32.32;
WES: whole exome sequencing; technique for sequencing protein-coding
genes; YAP1: Yes associated protein 1; nuclear effector of the Hippo
pathway; located at 11q13; ZNF14: zinc finger protein 14; located at
19p13.11; ZNF160: zinc finger protein 160; located at 19q13.42; ZNF420:
zinc finger protein 420; located at 19q13.12; ΔNp63α: isoform of the p53
homologue TP63 that lacks (ΔN) the transactivation domain.
Acknowledgements
The authors were supported by U54 CA149147, R21 CA181287, R21
CA191425 and P50 CA083638 from the NIH (to EAG), the Ruth L. Kirschstein
NRSA F30 fellowship (F30 CA180607) from the NIH (to TNB) and NCI Core
Grant P30 CA006927 (to Fox Chase Cancer Center).
Authors’ contributions
Conception and design: TNB. Collection and assembly of data: TNB. Data
analysis and interpretation: Both authors. Manuscript writing: Both authors.
Both authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Program in Molecular Therapeutics, Fox Chase Cancer Center, 333 Cottman
Ave, Philadelphia, PA 19111, USA. 2Program in Molecular and Cell Biology
and Genetics, Drexel University College of Medicine, Philadelphia, PA 19129,
USA.
Received: 22 January 2016 Accepted: 9 May 2016
References
1. Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak
AJ, Colevas AD, Dunphy F, Eisele DW et al. Head and Neck Cancers, Version
1.2015 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw.
2015;13(7):847–56.
2. Burtness B, Golemis EA. Overview: the pathobiology of head and neck
cancer. In: Burtness B, Golemis EA, editors. Molecular determinants of head
and neck cancer. 1st ed. New York: Springer New York; 2014. p. 1–5.
3. Dillon MT, Harrington KJ. Human papillomavirus-negative pharyngeal
cancer. J Clin Oncol. 2015;33(29):3251–61.
4. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J,
Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in
incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol.
2013;31(36):4550–9.
5. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human
papillomavirus-positive head and neck squamous cell carcinoma. J Clin
Oncol. 2015;33(29):3235–42.
6. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP,
Dal Maso L, Daudt AW, Fabianova E, Fernandez L et al. Alcohol drinking in
never users of tobacco, cigarette smoking in never drinkers, and the risk of
head and neck cancer: pooled analysis in the International Head and Neck
Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99(10):777–89.
7. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S.
Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal
head and neck cancer–systematic review and meta-analysis of trends by time
and region. Head Neck. 2013;35(5):747–55.
8. Chung CH, Bagheri A, D’Souza G. Epidemiology of oral human
papillomavirus infection. Oral Oncol. 2014;50(5):364–9.
9. Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer:
unique features of epidemiology and clinical management. Annu Rev Med.
2016;67:91–101.
10. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra
WH, Chung CH, Jordan RC, Lu C et al. Human papillomavirus and survival of
patients with oropharyngeal cancer. New Engl J Med. 2010;363(1):24–35.
11. Ang KK, Chen A, Curran Jr WJ, Garden AS, Harari PM, Murphy BA, et al. Head
and neck carcinoma in the United States: first comprehensive report of the
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN).
Cancer. 2012;118(23):5783–92.12. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin
Oncol. 2015;33(29):3293–304.
13. Huang SH, Xu W, Waldron J, Siu L, Shen X, Tong L, Ringash J, Bayley A, Kim J,
Hope A et al. Refining American Joint Committee on Cancer/Union for
International Cancer Control TNM stage and prognostic groups for human
papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015;33(8):836–45.
14. O’Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human
papillomavirus related head and neck cancer survival: a systematic review
and meta-analysis. Oral Oncol. 2012;48(12):1191–201.
15. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):
17–37.
16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW.
Cancer genome landscapes. Science. 2013;339(6127):1546–58.
17. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB,
Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM.
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;
45(10):1113–20.
18. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson
MDM, Niu BF, McLellan MD, Uzunangelov V et al. Multiplatform analysis of
12 cancer types reveals molecular classification within and across tissues of
origin. Cell. 2014;158(4):929–44.
19. Cancer Genome Atlas N. Comprehensive genomic characterization of head
and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.
20. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry
C, Xie TX, Zhang J, Wang J et al. Exome sequencing of head and neck
squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Science. 2011;333(6046):1154–7.
21. Seiwert TY, Zuo ZX, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C,
Pugh TJ, Stojanov P, Cho J et al. Integrative and Comparative Genomic
Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell
Carcinomas. Clin Cancer Res. 2015;21(3):632–41.
22. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A,
Kryukov GV, Lawrence MS, Sougnez C, McKenna A et al. The mutational
landscape of head and neck squamous cell carcinoma. Science. 2011;
333(6046):1157–60.
23. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q,
Du Y, Gilbert BR et al. Frequent mutation of the PI3K pathway in head and
neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–9.
24. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C.
Clonal status of actionable driver events and the timing of mutational
processes in cancer evolution. Sci Transl Med. 2015;7(283):283ra54.
25. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV,
Bignell GR, Bolli N, Borg A, Borresen-Dale AL et al. Signatures of mutational
processes in human cancer. Nature. 2013;500(7463):415–21.
26. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C.
Emerging landscape of oncogenic signatures across human cancers.
Nat Genet. 2013;45(10):1127–33.
27. Bhatia A, Burtness B. Human papillomavirus-associated oropharyngeal
cancer: defining risk groups and clinical trials. J Clin Oncol. 2015;33(29):
3243–50.
28. Vokes EE, Agrawal N, Seiwert TY. HPV-Associated Head and Neck Cancer.
J Natl Cancer Inst. 2015;107(12):djv344.
29. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head
and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.
30. McLaughlin-Drubin ME, Crum CP, Munger K. Human papillomavirus E7
oncoprotein induces KDM6A and KDM6B histone demethylase expression
and causes epigenetic reprogramming. Proc Natl Acad Sci U S A. 2011;
108(5):2130–5.
31. Munger K, Jones DL. Human papillomavirus carcinogenesis: an identity
crisis in the retinoblastoma tumor suppressor pathway. J Virol. 2015;
89(9):4708–11.
32. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J, Helin K.
The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-
ARF locus in response to oncogene- and stress-induced senescence. Genes
Dev. 2009;23(10):1171–6.
33. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R.
Distinct risk factor profiles for human papillomavirus type 16-positive and
human papillomavirus type 16-negative head and neck cancers. J Natl
Cancer Inst. 2008;100(6):407–20.
34. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow
CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD et al. Characterization
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 14 of 17of HPV and host genome interactions in primary head and neck cancers.
Proc Natl Acad Sci U S A. 2014;111(43):15544–9.
35. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M,
Ortega Alves MV, Chang K, Drummond J et al. Integrative genomic
characterization of oral squamous cell carcinoma identifies frequent somatic
drivers. Cancer Discov. 2013;3(7):770–81.
36. Pickering CR, Zhang JX, Neskey DM, Zhao M, Jasser SA, Wang JP, Ward A,
Tsai CJ, Alves MVO, Zhou JH et al. Squamous cell carcinoma of the oral
tongue in young Non-smokers is genomically similar to tumors in older
smokers. Clin Cancer Res. 2014;20(14):3842–8.
37. Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, Sato Y, Liu LZ, Ding
LW, Sharma A et al. The genomic landscape of nasopharyngeal carcinoma.
Nat Genet. 2014;46(8):866–71.
38. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC,
Jacobsen A, Sinha R, Larsson E et al. Integrative analysis of complex
cancer genomics and clinical profiles using the cBioPortal. Sci Signal.
2013;6(269):pl1.
39. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio
cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer Discov. 2012;2(5):401–4.
40. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G.
GISTIC2.0 facilitates sensitive and confident localization of the targets of
focal somatic copy-number alteration in human cancers. Genome Biol.
2011;12(4):R41.
41. Masuda M, Yamada T. Signaling pathway profiling by reverse-phase protein
array for personalized cancer medicine. Biochim Biophys Acta. 2015;1854(6):
651–7.
42. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al.
NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids
Res. 2013;41(D1):D991–5.
43. Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human
papillomavirus-associated head and neck cancer and comparison to
tobacco-related tumors. J Clin Oncol. 2015;33(29):3227–34.
44. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, et al. Molecular
subtypes in head and neck cancer exhibit distinct patterns of chromosomal
gain and loss of canonical cancer genes. PLoS One. 2013;8(2):e56823.
45. Tai SK, Lee JI, Ang KK, El-Naggar AK, Hassan KA, Liu D, et al. Loss of FHIT
expression in head and neck squamous cell carcinoma and its potential
clinical implication. Clin Cancer Res. 2004;10(16):5554–7.
46. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, et al.
Characterization CSMD1 in a large set of primary lung, head and neck,
breast and skin cancer tissues. Cancer Biol Ther. 2009;8(10):907–16.
47. Scholnick SB, Richter TM. The role of CSMD1 in head and neck
carcinogenesis. Genes Chromosomes Cancer. 2003;38(3):281–3.
48. Cancer Genome Atlas Research N. Comprehensive genomic characterization
of squamous cell lung cancers. Nature. 2012;489(7417):519–25.
49. Liu Z, Long XB, Chao C, Yan C, Wu QY, Hua SN, Zhang YJ, Wu AB, Fang WY.
Knocking down CDK4 mediates the elevation of let-7c suppressing cell
growth in nasopharyngeal carcinoma. Bmc Cancer. 2014;14:274.
50. Liu N, Boohaker RJ, Jiang C, Boohaker JR, Xu B. A radiosensitivity MiRNA
signature validated by the TCGA database for head and neck squamous
cell carcinomas. Oncotarget. 2015;6(33):34649–57.
51. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms,
modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24.
52. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in
human cancer. Nat Rev Cancer. 2002;2(7):489–501.
53. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. AXL
mediates resistance to PI3K alpha inhibition by activating the EGFR/PKC/
mTOR axis in head and neck and esophageal squamous cell carcinomas.
Cancer Cell. 2015;27(4):533–46.
54. Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I,
et al. Mutant PIK3CA promotes cell growth and invasion of human cancer
cells. Cancer Cell. 2005;7(6):561–73.
55. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, et al. PIK3CA
mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK
and mutant KRAS signaling. Cancer Res. 2010;70(17):6804–14.
56. Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, et al. Phospho-
T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the
head and neck. Oncotarget. 2015;6(22):18863–74.
57. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al.
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 inHER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci
U S A. 2009;106(52):22299–304.
58. Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, et al.
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor
PF-5212384 and potentiates antitumor effects in Human Head and Neck
Squamous Cell Carcinoma. Clin Cancer Res. 2015;21(17):3946–56.
59. Herzog A, Bian YS, Vander Broek R, Hall B, Coupar J, Cheng H, et al. PI3K/
mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction
of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of
Head and Neck Cancer. Clin Cancer Res. 2013;19(14):3808–19.
60. Rodon J, Dienstmann R, Serra V, Tabemero J. Development of PI3K
inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol.
2013;10(3):143–53.
61. Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control.
Nat Rev Cancer. 2009;9(8):587–95.
62. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al.
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet.
2003;33(3):416–21.
63. Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1
activation involves Wnt-beta-catenin down-regulation in human tongue
carcinoma cells. Biol Cell. 2006;98(8):479–90.
64. Dotto GP. Notch tumor suppressor function. Oncogene. 2008;27(38):
5115–23.
65. Okuyama R, Ogawa E, Nagoshi H, Yabuki M, Kurihara A, Terui T, et al. p53
homologue, p51/p63, maintains the immaturity of keratinocyte stem cells
by inhibiting Notch1 activity. Oncogene. 2007;26(31):4478–88.
66. Yang AN, Kaghad M, Wang YM, Gillett E, Fleming MD, Dotsch V, et al. p63,
a p53 homolog at 3q27-29, encodes multiple products with
transactivating, death-inducing, and dominant-negative activities.
Mol Cell. 1998;2(3):305–16.
67. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, et al.
DeltaNp63alpha and TAp63alpha regulate transcription of genes with
distinct biological functions in cancer and development. Cancer Res. 2003;
63(10):2351–7.
68. Westfall MD, Pietenpol JA. p63: Molecular complexity in development and
cancer. Carcinogenesis. 2004;25(6):857–64.
69. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting
with mutant p53. Cell Death Differ. 2011;18(9):1487–99.
70. Zangen R, Ratovitski E, Sidransky D. Delta Np63 alpha levels correlate with
clinical tumor response to cisplatin. Cell Cycle. 2005;4(10):1313–5.
71. Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, et al. Tumor
suppressor gene p16 (CDKN2A) mutation status and promoter inactivation
in head and neck cancer. Int J Mol Med. 1999;4(1):61–5.
72. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53
tumor suppressor gene: clues to cancer etiology and molecular
pathogenesis. Cancer Res. 1994;54(18):4855–78.
73. Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and
neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013;
14(8):e302–9.
74. Jensen MA, Fukushima M, Davis RW. DMSO and betaine greatly improve
amplification of GC-rich constructs in de novo synthesis. PLoS One. 2010;
5(6):e11024.
75. Kozarewa I, Ning Z, Quail MA, Sanders MJ, Berriman M, Turner DJ. Amplification-
free Illumina sequencing-library preparation facilitates improved mapping and
assembly of (G + C)-biased genomes. Nat Methods. 2009;6(4):291–5.
76. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA,
et al. TP53 mutations and survival in squamous-cell carcinoma of the head
and neck. N Engl J Med. 2007;357(25):2552–61.
77. Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, et al. Predicting
survival in head and neck squamous cell carcinoma from TP53 mutation.
Hum Genet. 2015;134(5):497–507.
78. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, et al. Multi-
tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p
loss. Nat Genet. 2014;46(9):939–43.
79. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 2014;
509(7498):91–5.
80. Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, et al.
Evolutionary action score of TP53 identifies high-risk mutations associated
with decreased survival and increased distant metastases in head and neck
cancer. Cancer Res. 2015;75(7):1527–36.
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 15 of 1781. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, et al.
Evolutionary action score of TP53 coding variants is predictive of
platinum response in head and neck cancer patients. Cancer Res. 2015;
75(7):1205–15.
82. Katsonis P, Lichtarge O. A formal perturbation equation between genotype
and phenotype determines the evolutionary action of protein-coding
variations on fitness. Genome Res. 2014;24(12):2050–8.
83. Brosh R, Rotter V. When mutants gain new powers: news from the mutant
p53 field. Nat Rev Cancer. 2009;9(10):701–13.
84. Lichtarge O, Wilkins A. Evolution: a guide to perturb protein function and
networks. Curr Opin Struc Biol. 2010;20(3):351–9.
85. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;
81(3):323–30.
86. Burke JR, Hura GL, Rubin SM. Structures of inactive retinoblastoma protein
reveal multiple mechanisms for cell cycle control. Gene Dev. 2012;26(11):
1156–66.
87. Wong SQ, Li J, Salemi R, Sheppard KE, Do H, Tothill RW, et al.
Targeted-capture massively-parallel sequencing enables robust detection
of clinically informative mutations from formalin-fixed tumours. Sci Rep.
2013;3:3494.
88. Demokan S, Chuang A, Suoglu Y, Ulusan M, Yalniz Z, Califano JA, et al.
Promoter methylation and loss of p16INK4a gene expression in head and
neck cancer. Head Neck-J Sci Spec. 2012;34(10):1470–5.
89. El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, et al.
Methylation, a major mechanism of p16/CDKN2 gene inactivation in head
and neck squamous carcinoma. Am J Pathol. 1997;151(6):1767–74.
90. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al. High
frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck
squamous cell carcinoma. Cancer Res. 1996;56(16):3630–3.
91. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-
suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006;7(1):
77–82.
92. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al. p16
protein expression and human papillomavirus status as prognostic
biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
J Clin Oncol. 2014;32(35):3930–U3212.
93. Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck
squamous cell carcinoma. Clin Cancer Res. 2015;21(3):526–33.
94. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2
overcomes resistance to cetuximab in a novel in vivo model of acquired
cetuximab resistance. Clin Cancer Res. 2011;17(18):5935–44.
95. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR
resistance networks in head and neck cancer. Cell Signal. 2009;21(8):1255–68.
96. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, et al.
Fibroblast growth factor receptors are components of autocrine signaling
networks in head and neck squamous cell carcinoma cells. Clin Cancer Res.
2011;17(15):5016–25.
97. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage.
Nat Rev Mol Cell Biol. 2004;5(11):875–85.
98. Weber CK, Slupsky JR, Herrmann C, Schuler M, Rapp UR, Block C. Mitogenic
signaling of Ras is regulated by differential interaction with Raf isozymes.
Oncogene. 2000;19(2):169–76.
99. Logue JS, Morrison DK. Complexity in the signaling network: insights
from the use of targeted inhibitors in cancer therapy. Gene Dev. 2012;
26(7):641–50.
100. Morris LGT, Kaufman AM, Gong YX, Ramaswami D, Walsh LA, Turcan S, et al.
Recurrent somatic mutation of FAT1 in multiple human cancers leads to
aberrant Wnt activation. Nat Genet. 2013;45(3):253–61.
101. Haraguchi K, Ohsugi M, Abe Y, Semba K, Akiyama T, Yamamoto T. Ajuba
negatively regulates the Wnt signaling pathway by promoting GSK-3beta-
mediated phosphorylation of beta-catenin. Oncogene. 2008;27(3):274–84.
102. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL, Golemis EA. Aurora A
kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci.
2013;70(4):661–87.
103. Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases
in head and neck cancer. Lancet Oncol. 2013;14(10):e425–35.
104. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling
pathway in cancer. Genes Dev. 2013;27(20):2179–91.
105. Cullinan SB, Gordan JD, Jin JO, Harper JW, Diehl JA. The Keap1-BTB protein
is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: Oxidative stress
sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477–86.106. Qian Z, Zhou T, Gurguis CI, Xu X, Wen Q, Lv J, et al. Nuclear factor, erythroid
2-like 2-associated molecular signature predicts lung cancer survival. Sci
Rep. 2015;5:16889.
107. Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from genomic
studies of head and neck squamous cell carcinomas. Cancer Discov. 2015;
5(3):239–44.
108. Martinez VD, Vucic EA, Thu KL, Pikor LA, Lam S, Lam WL. Disruption of
KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple
genetic mechanisms: association with poor prognosis in head and neck
cancer. Head Neck-J Sci Spec. 2015;37(5):727–34.
109. Choschzick M, Tabibzada AM, Gieseking F, Woelber L, Jaenicke F, Sauter G,
et al. BIRC2 amplification in squamous cell carcinomas of the uterine cervix.
Virchows Arch. 2012;461(2):123–8.
110. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al. Expression
of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical
cancers to radiotherapy. Cancer Res. 2002;62(17):4860–6.
111. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, et al.
Identification of cIAP1 as a candidate target gene within an amplicon at
11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001;61(18):
6629–34.
112. Phillips AH, Schoeffler AJ, Matsui T, Weiss TM, Blankenship JW, Zobel K, et al.
Internal motions prime cIAP1 for rapid activation. Nat Struct Mol Biol. 2014;
21(12):1068–74.
113. Vallabhapurapu S, Matsuzawa A, Zhang WZ, Tseng PH, Keats JJ, Wang HP,
et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in
a ubiquitination cascade that activates NIK-dependent alternative NF-kappa
B signaling. Nat Immunol. 2008;9(12):1364–70.
114. Stanger BZ. Quit your YAPing: a new target for cancer therapy. Gene Dev.
2012;26(12):1263–7.
115. Jerhammar F, Johansson AC, Ceder R, Welander J, Jansson A, Grafstrom RC,
et al. YAP1 is a potential biomarker for cetuximab resistance in head and
neck cancer. Oral Oncol. 2014;50(9):832–9.
116. Zhang JM, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-
dependent induction of amphiregulin identifies a non-cell-autonomous
component of the Hippo pathway. Nat Cell Biol. 2009;11(12):1444–U1134.
117. Pattje WJ, Melchers LJ, Slagter-Menkema L, Mastik MF, Schrijvers ML, Gibcus
JH, et al. FADD expression is associated with regional and distant metastasis
in squamous cell carcinoma of the head and neck. Histopathology. 2013;
63(2):263–70.
118. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, et al.
Targeted next-generation sequencing of head and neck squamous cell
carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.
Genome Med. 2013;5(5):49.
119. Khoury JD, Tannir NM, Williams MD, Chen YX, Yao H, Zhang JP, et al.
Landscape of DNA virus associations across human malignant cancers:
analysis of 3775 cases using RNA-Seq. J Virol. 2013;87(16):8916–26.
120. Wentzensen N, Vinokurova S, Doeberitz MV. Systematic review of genomic
integration sites of human papillomavirus genomes in epithelial dysplasia
and invasive cancer of the female lower genital tract. Cancer Res. 2004;
64(11):3878–84.
121. Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, et al. Genome-wide profiling of
HPV integration in cervical cancer identifies clustered genomic hot spots
and a potential microhomology-mediated integration mechanism. Nat
Genet. 2015;47(2):158–63.
122. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to
transformation. Nat Rev Cancer. 2010;10(8):550–60.
123. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the
molecular pathogenesis of HPV. Oncogene. 1999;18(53):7690–700.
124. Huh K, Zhou XB, Hayakawa H, Cho JY, Libermann TA, Jin JP, et al. Human
papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin
ligase complex, which contributes to degradation of the retinoblastoma
tumor suppressor. J Virol. 2007;81(18):9737–47.
125. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16
E7-oncoprotein is able to bind to the retinoblastoma gene-product.
Science. 1989;243(4893):934–7.
126. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its
role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15(22):
6758–62.
127. Singh P, Thomas GE, Gireesh KK, Manna TK. TACC3 protein regulates
microtubule nucleation by affecting gamma-tubulin ring complexes. J Biol
Chem. 2014;289(46):31719–35.
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 16 of 17128. Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H, et al. A small
compound targeting TACC3 revealed its different spatiotemporal
contributions for spindle assembly in cancer cells. Oncogene. 2014;33(33):
4242–52.
129. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al.
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma.
Science. 2012;337(6099):1231–5.
130. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al.
Identification of targetable FGFR gene fusions in diverse cancers. Cancer
Discov. 2013;3(6):636–47.
131. Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS. Recurrent FGFR3-TACC3 fusion
gene in nasopharyngeal carcinoma. Cancer Biol Ther. 2014;15(12):1613–21.
132. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced
immune regulator. Nat Rev Immunol. 2011;11(7):457–68.
133. Zhang J, Chen H, Yang X, Guven E, Nussinov R, Chen Z, VanWaes C.
Defective TRAF3 modulates alternative NF-kB signaling and cytokine
expression to promote cancer cell survival in HPV positive head and neck
cancer (TUM10P.1049). J Immunol. 2015;194:211.30.
134. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor
heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26.
135. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al.
Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015;
21(8):846–53.
136. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.
Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N Engl J Med. 2012;366(10):883–92.
137. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic
heterogeneity, is high in poor-outcome classes of head and neck squamous
cell carcinoma. Oral Oncol. 2013;49(3):211–5.
138. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW. Intra-tumor genetic
heterogeneity and mortality in head and neck cancer: analysis of data from
the Cancer Genome Atlas. Plos Med. 2015;12(2):e1001786.
139. Landau DA, Carter SL, Getz G, Wu CJ. Clonal evolution in hematological
malignancies and therapeutic implications. Leukemia. 2014;28(1):34–43.
140. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS,
et al. Evolution and impact of subclonal mutations in chronic lymphocytic
leukemia. Cell. 2013;152(4):714–26.
141. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al.
Widespread genetic heterogeneity in multiple myeloma: implications for
targeted therapy. Cancer Cell. 2014;25(1):91–101.
142. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute
quantification of somatic DNA alterations in human cancer. Nat Biotechnol.
2012;30(5):413–21.
143. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes:
mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov.
2015;5(7):704–12.
144. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated
cytosine deamination links PIK3CA helical domain mutations to human
papillomavirus-driven tumor development. Cell Rep. 2014;7(6):1833–41.
145. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha
of phosphatidylinositol 3-kinase induce gain of function by different
mechanisms. Proc Natl Acad Sci U S A. 2008;105(7):2652–7.
146. Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, et al. Patterns
and functional implications of rare germline variants across 12 cancer types.
Nat Commun. 2015;6:10086.
147. Moldovan GL, D’Andrea AD. How the Fanconi Anemia pathway guards the
genome. Annu Rev Genet. 2009;43:223–49.
148. Conti MA, Saleh AD, Brinster LR, Cheng H, Chen Z, Cornelius S, et al.
Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium
results in squamous cell carcinoma. Sci Rep. 2015;5:14068.
149. Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, et al. Direct
in Vivo RNAi Screen Unveils Myosin IIa as a Tumor Suppressor of Squamous
Cell Carcinomas. Science. 2014;343(6168):309–13.
150. Ma X, Adelstein RS. The role of vertebrate nonmuscle Myosin II in
development and human disease. Bioarchitecture. 2014;4(3):88–102.
151. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, et al. Evolutionary
dynamics of cancer in response to targeted combination therapy. Elife.
2013;2:e00747.
152. Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, et al.
Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing
trials, critical issues and perspectives. Int J Cancer. 2015;136(7):1494–503.153. Liu H, Cracchiolo JR, Beck TN, Serebriiskii IG, Golemis EA. EGFR inhibitors as
therapeutic agents in head and neck cancer. In: Burtness B, Golemis EA,
editors. Molecular determinants of head and neck cancer. 1st ed. New York:
Springer New York; 2014. p. 55–90.
154. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N
Engl J Med. 2008;359(11):1116–27.
155. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern
Cooperative Oncology G. Phase III randomized trial of cisplatin plus placebo
compared with cisplatin plus cetuximab in metastatic/recurrent head and
neck cancer: an eastern cooperative oncology group study. J Clin Oncol.
2005;23(34):8646–54.
156. Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza
FH, et al. Randomised Phase II study of oral lapatinib combined with
chemoradiotherapy in patients with advanced squamous cell carcinoma
of the head and neck: rationale for future randomised trials in human
papilloma virus-negative disease. Eur J Cancer. 2013;49(7):1609–18.
157. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB,
et al. Afatinib versus methotrexate as second-line treatment in patients
with recurrent or metastatic squamous-cell carcinoma of the head and
neck progressing on or after platinum-based therapy (LUX-Head & Neck
1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(5):
583–94.
158. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted
therapies in cancer. Nat Med. 2013;19(11):1389–400.
159. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head
and neck cancer. Drugs. 2013;73(4):315–25.
160. Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer:
molecular oncology of head and neck cancer. Cell Death Dis. 2014;5:e1018.
161. Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic
head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3305–13.
162. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of
targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov.
2015;14(2):130–46.
163. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene
rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772–
87.
164. Huang M, Shen AJ, Ding J, Geng MY. Molecularly targeted cancer therapy:
some lessons from the past decade. Trends Pharmacol Sci. 2014;35(1):41–50.
165. Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, et al. The
radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF alpha-
mediated in head and neck squamous cell carcinoma. Radiother Oncol.
2015;116(3):495–503.
166. Eytan DF, Snow GE, Carlson SG, Schiltz S, Chen Z, Van Waes C. Combination
effects of SMAC mimetic birinapant with TNFalpha, TRAIL, and docetaxel in
preclinical models of HNSCC. Laryngoscope. 2015;125(3):E118–24.
167. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer
immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov.
2015;14(8):561–84.
168. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall
Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1
Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated
Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(18):2004–
U2032.
169. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung
cancer. N Engl J Med. 2015;373(17):1627–39.
170. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med. 2010;363(8):711–23.
171. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1
blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;
372(26):2509–20.
172. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in
cancer therapy. J Clin Oncol. 2015;33(17):1974–82.
173. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased
absolute counts of T lymphocyte subsets and their relation to disease
in squamous cell carcinoma of the head and neck. Clin Cancer Res.
2004;10(11):3755–62.
174. Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-
4(+) regulatory T cells increased in cetuximab-treated head and neck cancer
Beck and Golemis Cancers of the Head & Neck  (2016) 1:1 Page 17 of 17patients suppress NK cell cytotoxicity and correlate with poor prognosis.
Cancer Res. 2015;75(11):2200–10.
175. Pardoll DM. The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
176. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
2015;372(26):2521–32.
177. Garon EB, Rizvi NA, Hui RN, Leighl N, Balmanoukian AS, Eder JP, et al.
Pembrolizumab for the treatment of non-small-cell lung cancer.
New Engl J Med. 2015;372(21):2018–28.
178. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-
refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Lancet Oncol. 2015;16(8):908–18.
179. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM,
et al. Commensal Bifidobacterium promotes antitumor immunity and
facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.
180. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al.
Anticancer immunotherapy by CTLA-4 blockade relies on the gut
microbiota. Science. 2015;350(6264):1079–84.
181. Weisenberger DJ. Characterizing DNA methylation alterations from the
Cancer Genome Atlas. J Clin Invest. 2014;124(1):17–23.
182. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.
183. Lleras RA, Smith RV, Adrien LR, Schlecht NF, Burk RD, Harris TM, et al.
Unique DNA methylation loci distinguish anatomic site and HPV status
in head and neck squamous cell carcinoma. Clin Cancer Res. 2013;
19(19):5444–55.
184. Schlecht NF, Ben-Dayan M, Anayannis N, Lleras RA, Thomas C, Wang Y, et al.
Epigenetic changes in the CDKN2A locus are associated with differential
expression of P16INK4A and P14ARF in HPV-positive oropharyngeal
squamous cell carcinoma. Cancer Med. 2015;4(3):342–53.
185. Gaykalova DA, Vatapalli R, Wei Y, Tsai HL, Wang H, Zhang C, et al.
Outlier analysis defines zinc finger gene family DNA methylation in
tumors and saliva of head and neck cancer patients. PLoS One. 2015;
10(11):e0142148.
186. Timmermann S, Hinds PW, Munger K. Re-expression of endogenous
p16(ink4a) in oral squamous cell carcinoma lines by 5-aza-2
'-deoxycytidine treatment induces a senescence-like state. Oncogene.
1998;17(26):3445–53.
187. Shi H, Chen X, Lu C, Gu CM, Jiang HW, Meng RW, Niu X, Huang YX, Lu MX.
Association between P16(INK4a) promoter methylation and HNSCC:
a meta-analysis of 21 published studies. Plos One. 2015;10(4):e0122302.
188. Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M,
et al. HPV-related methylation signature predicts survival in oropharyngeal
squamous cell carcinomas. J Clin Invest. 2013;123(6):2488–501.
189. Shi H, Chen X, Lu C, Gu C, Jiang H, Meng R, et al. Association between
P16INK4a promoter methylation and HNSCC: a meta-analysis of 21
published studies. PLoS One. 2015;10(4):e0122302.
190. Chen X, Liu L, Mims J, Punska EC, Williams KE, Zhao W, et al. Analysis of
DNA methylation and gene expression in radiation-resistant head and neck
tumors. Epigenetics. 2015;10(6):545–61.
191. Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C,
Rouleau E, Vincent-Salomon A, Servant N, Alt M, et al. Treatment algorithms
based on tumor molecular profiling: the essence of precision medicine
trials. J Natl Cancer Inst. 2016;108(4):djv362.
192. Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio Frio T, et al.
Randomised proof-of-concept phase II trial comparing targeted therapy
based on tumour molecular profiling vs conventional therapy in patients
with refractory cancer: results of the feasibility part of the SHIVA trial. Br J
Cancer. 2014;111(1):17–24.
193. Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, et al.
Challenges in initiating and conducting personalized cancer therapy trials:
perspectives from WINTHER, a Worldwide Innovative Network (WIN)
Consortium trial. Ann Oncol. 2015;26(8):1791–8.
194. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al.
Neo-antigens predicted by tumor genome meta-analysis correlate with
increased patient survival. Genome Res. 2014;24(5):743–50.
195. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al.
Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung
cancer. N Engl J Med. 2015;373(2):123–35.196. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM,
et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med.
2013;369(2):122–33.
197. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ,
et al. Cancer immunology. Mutational landscape determines sensitivity
to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):
124–8.
198. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV
vaccines: summary of early evidence. J Adolesc Health. 2013;53(6):
679–82.
199. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human
papillomavirus vaccination on cervical neoplasia–nationwide follow-up of
young Danish women. J Natl Cancer Inst. 2014;106(3):djt460.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
